274 related articles for article (PubMed ID: 24836740)
1. Vagomimetic effects of fingolimod: physiology and clinical implications.
Vanoli E; Pentimalli F; Botto G
CNS Neurosci Ther; 2014 Jun; 20(6):496-502. PubMed ID: 24836740
[TBL] [Abstract][Full Text] [Related]
2. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
Scott LJ
CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
[TBL] [Abstract][Full Text] [Related]
3. Fingolimod for the treatment of relapsing multiple sclerosis.
Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
[TBL] [Abstract][Full Text] [Related]
4. Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.
Voon V; Saiva L; O'Kelly S; Keane D
Eur J Clin Pharmacol; 2014 Mar; 70(3):373-5. PubMed ID: 24309839
[No Abstract] [Full Text] [Related]
5. [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
Széplaki G; Merkely B
Ideggyogy Sz; 2012 Nov; 65(11-12):369-76. PubMed ID: 23289171
[TBL] [Abstract][Full Text] [Related]
6. Fingolimod for relapsing multiple sclerosis: an update.
Horga A; Castilló J; Montalban X
Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
[TBL] [Abstract][Full Text] [Related]
7. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
Gold R; Comi G; Palace J; Siever A; Gottschalk R; Bijarnia M; von Rosenstiel P; Tomic D; Kappos L;
J Neurol; 2014 Feb; 261(2):267-76. PubMed ID: 24221641
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
10. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
Vasiliou S
Drugs Today (Barc); 2010 May; 46(5):315-25. PubMed ID: 20517533
[TBL] [Abstract][Full Text] [Related]
11. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Singer B; Ross AP; Tobias K
Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
[TBL] [Abstract][Full Text] [Related]
12. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
Massberg S; von Andrian UH
N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
[No Abstract] [Full Text] [Related]
13. Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.
Limmroth V; Ziemssen T; Lang M; Richter S; Wagner B; Haas J; Schmidt S; Gerbershagen K; Lassek C; Klotz L; Hoffmann O; Albert C; Schuh K; Baier-Ebert M; Wendt G; Schieb H; Hoyer S; Dechend R; Haverkamp W
BMC Neurol; 2017 Jan; 17(1):11. PubMed ID: 28100182
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
Chun J; Hartung HP
Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
[TBL] [Abstract][Full Text] [Related]
15. Effects of fingolimod in relapsing-remitting multiple sclerosis.
Sorensen PS
Lancet Neurol; 2014 Jun; 13(6):526-7. PubMed ID: 24685277
[No Abstract] [Full Text] [Related]
16. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
Groves A; Kihara Y; Chun J
J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
[TBL] [Abstract][Full Text] [Related]
17. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
18. Sphingosine 1-phosphate receptor agonists: a patent review (2010-2012).
Roberts E; Guerrero M; Urbano M; Rosen H
Expert Opin Ther Pat; 2013 Jul; 23(7):817-41. PubMed ID: 23541049
[TBL] [Abstract][Full Text] [Related]
19. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.
Huggins A; Sergott RC
Curr Opin Ophthalmol; 2011 Nov; 22(6):447-50. PubMed ID: 21946305
[No Abstract] [Full Text] [Related]
20. [Infections and fingolimod].
Cervera C
Rev Neurol; 2012 Aug; 55(4):227-37. PubMed ID: 22829086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]